Literature DB >> 21185007

Safety of lower activated clotting times during atrial fibrillation ablation using open irrigated tip catheters and a single transseptal puncture.

Roger A Winkle1, R Hardwin Mead, Gregory Engel, Rob A Patrawala.   

Abstract

Guidelines largely based on closed-tip catheters recommend activated clotting times (ACTs) >300 to 350 seconds during atrial fibrillation (AF) ablation to prevent thrombus and char formation. Open irrigated tip catheters (OITC) may decrease complications and permit lower ACTs. This study evaluated factors contributing to vascular and hemorrhagic complications during AF ablation with emphasis on catheter type, anticoagulation level, procedural and clinical variables, and gender. In 1,122 AF ablations we examined catheter used, ACT level, gender, and complications. Target ACTs initially were >300 seconds and were decreased to 225 seconds for the OITC. Average ACT ranges were created: <250, 250 to 299, 300 to 350, and >350 seconds. Average ACT was <250 seconds in 557 ablations (complication rate 1.62%). Cochran-Armitage analysis showed that complications increased linearly as ACT increased and peaked at 5.55% for ablations with ACTs >350 seconds (p = 0.038). Women were older (66 ± 10 vs 60 ± 10 years, p <0.001) and had more paroxysmal AF (43% vs 28%, p = 0.007) and more hypertension (50% vs 40%, p = 0.013). Women received less heparin but were over-represented in higher ACT ranges (p <0.0001) consistent with a pharmacokinetic gender difference. There was no difference in vascular or hemorrhagic complications between men and women (2.3% vs 2.9%, p = 0.668). Multivariate logistic regression showed that only use of the OITC was associated with lower complication rates (p = 0.024). In conclusion, AF ablation with the OITC is safe with a target ACT of 225 seconds.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21185007     DOI: 10.1016/j.amjcard.2010.10.048

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Periprocedural dabigatran anticoagulation for atrial fibrillation ablation: do we have enough information to make a rational decision.

Authors:  Amit Noheria; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2013-07-28       Impact factor: 1.900

Review 2.  Sex Differences In Outcomes Of Ablation Of Atrial Fibrillation.

Authors:  Hiroko Beck; Anne B Curtis
Journal:  J Atr Fibrillation       Date:  2014-04-30

3.  Trends in atrial fibrillation ablation: have we maximized the current paradigms?

Authors:  Roger A Winkle; R Hardwin Mead; Gregory Engel; Melissa H Kong; Rob A Patrawala
Journal:  J Interv Card Electrophysiol       Date:  2012-02-28       Impact factor: 1.900

4.  Prior antiarrhythmic drug use and the outcome of atrial fibrillation ablation.

Authors:  Roger A Winkle; R Hardwin Mead; Gregory Engel; Melissa H Kong; Rob A Patrawala
Journal:  Europace       Date:  2012-02-06       Impact factor: 5.214

5.  Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.

Authors:  Roger A Winkle; R Hardwin Mead; Gregory Engel; Melissa H Kong; Rob A Patrawala
Journal:  Europace       Date:  2014-08-12       Impact factor: 5.214

6.  Patients with hemophilia: Unique challenges for atrial fibrillation management.

Authors:  Jeffrey Y Lin; Petar Igic; Kurt S Hoffmayer; Michael E Field
Journal:  HeartRhythm Case Rep       Date:  2015-09-03

Review 7.  Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia.

Authors:  Minerva Codruta Badescu; Oana Viola Badulescu; Lacramioara Ionela Butnariu; Mariana Floria; Manuela Ciocoiu; Irina-Iuliana Costache; Diana Popescu; Ioana Bratoiu; Oana Nicoleta Buliga-Finis; Ciprian Rezus
Journal:  J Pers Med       Date:  2022-03-23

8.  Physician-controlled costs: the choice of equipment used for atrial fibrillation ablation.

Authors:  Roger A Winkle; R Hardwin Mead; Gregory Engel; Melissa H Kong; Rob A Patrawala
Journal:  J Interv Card Electrophysiol       Date:  2013-03-14       Impact factor: 1.900

9.  Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes.

Authors:  Roger A Winkle; R Hardwin Mead; Gregory Engel; Melissa H Kong; Rob A Patrawala
Journal:  J Interv Card Electrophysiol       Date:  2013-10-08       Impact factor: 1.900

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.